Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 4/20 | 0.50 |
| ▸ | HSPA2 | P54652 | 2/20 | 0.50 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.50 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375203 | 0.92 | CTSL (0.53) | HSPA5HSPA2HSPA1AHSPA9CTSL | |
| SCHEMBL17994251 | 0.90 | HSPA5 (0.50) | HSPA5HSPA2HSPA1AHSPA9CTSL | |
| SCHEMBL17994242 | 0.89 | HSPA5 (0.48) | HSPA5HSPA2HSPA1AHSPA9CTSL | |
| SCHEMBL17994239 | 0.87 | MME (0.49) | CTSLMMEANPEP | |
| SCHEMBL17994240 | 0.85 | CTSL (0.53) | HSPA5HSPA2HSPA1AHSPA9CTSL | |
| SCHEMBL16375208 | 0.81 | HSPA5 (0.51) | HSPA5HSPA2HSPA1AHSPA9CTSL | |
| SCHEMBL16375213 | 0.81 | HSPA1A (0.53) | HSPA5HSPA2HSPA1AHSPA9CTSL | |
| SCHEMBL16375200 | 0.80 | MME (0.53) | CTSLMMEANPEP | |
| SCHEMBL17994253 | 0.80 | HSPA5 (0.43) | HSPA5HSPA2HSPA1AHSPA9CTSL | |
| SCHEMBL17834782 | 0.78 | MME (0.45) | MMEANPEPHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | HSPA5 3669/4885HSPA2 3462/4885HSPA1A 2012/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | HSPA5 3669/4885HSPA2 3462/4885HSPA1A 2012/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | HSPA5 3743/4885HSPA2 3475/4885HSPA1A 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.